FDA-cleared profile

Median LCS (internal name) / eyonis LCS (trade name) (1.0)

Median Technologies · CT/CTA · FDA-cleared (510(k))

eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.

Clinical role
Concurrent-read CADe/CADx software that detects, localizes and characterizes pulmonary nodules on low-dose chest CT and generates a result report giving each nodule a malignancy score, displayed alongside the original CT images; it does not replace the interpreting physician's judgement.
Images and patients
CT/CTA · Chest/Lung
Key limitation
Does not replace physician judgment; intended for the stated 4-30 mm solid and part-solid nodule context and high-risk screening population.

Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • Imaging and anatomyCT/CTA · Chest/Lung
  • Workflow roleConcurrent-read CADe/CADx software that detects, localizes and characterizes pulmonary nodules on low-dose chest CT and generates a result report giving each nodule a malignancy score, displayed alongside the original CT images; it does not replace the interpreting physician's judgement.
  • Required inputLow-dose chest CT DICOM images from high-risk patients eligible for lung cancer screening programs (as per USPSTF criteria), excluding patients with pure ground glass cancer only and hilar/mediastinal cancer; exact specifications are described in a DICOM Conformance Statement.
  • Output and human actionNodule detection, localization, characterization, measurements, and malignancy scores for radiologist review.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.
  • Exact FDA submission
  • Checked 2026-08-13
Workflow role
Concurrent-read CADe/CADx software that detects, localizes and characterizes pulmonary nodules on low-dose chest CT and generates a result report giving each nodule a malignancy score, displayed alongside the original CT images; it does not replace the interpreting physician's judgement.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "eyonis® LCS is an AI/ML technology-based end-to-end CADe/CADx Software as a Medical Device (SaMD) designed to enable early detection, localization and characterization of pulmonary parenchymal nodules on low-dose Chest CT images" … "As an output, eyonis® LCS generates a result report that highlights probably benign, suspicious and very suspicious nodules and scores them individually by giving a malignancy score". Read from the exact FDA decision document on 2026-11-14.

Required input
Low-dose chest CT DICOM images from high-risk patients eligible for lung cancer screening programs (as per USPSTF criteria), excluding patients with pure ground glass cancer only and hilar/mediastinal cancer; exact specifications are described in a DICOM Conformance Statement.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "It is indicated for use with low-dose Chest CT DICOM images. The exact specifications are described in a DICOM Conformance Statement (DCS) document." … "The target population is high-risk patients eligible for participation in lung cancer screening programs (as per USPSTF criteria) with the exception of patients with pure ground glass cancer only and hilar/mediastinal cancer who are excluded from the intended population.". Read from the exact FDA decision document on 2026-11-14.

Output and clinician action
Nodule detection, localization, characterization, measurements, and malignancy scores for radiologist review.
  • Exact FDA submission
  • Checked 2026-08-13
Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Radiologists interpreting low-dose chest CT for high-risk lung cancer screening.
  • Exact FDA submission
  • Checked 2026-08-13
Limitations
Does not replace physician judgment; intended for the stated 4-30 mm solid and part-solid nodule context and high-risk screening population.
  • Exact FDA submission
  • Checked 2026-08-13
Evidence summary
Two completed sponsor-registered retrospective studies describe Median LCS / eyonis LCS: RELIVE evaluated assisted versus unassisted reader accuracy in 480 high-risk lung-cancer screening cases, and REALITY evaluated standalone performance in 1,147 cases. The registry records identify the product family but not FDA submission K251474 or a software version.
  • Product family
  • Checked 2026-09-01

Registry records establish study design and enrollment, not peer-reviewed results or exact-version equivalence.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Two completed sponsor-registered retrospective studies describe Median LCS / eyonis LCS: RELIVE evaluated assisted versus unassisted reader accuracy in 480 high-risk lung-cancer screening cases, and REALITY evaluated standalone performance in 1,147 cases. The registry records identify the product family but not FDA submission K251474 or a software version.
  • Public source
  • Product family
  • Checked 2026-09-01

Registry records establish study design and enrollment, not peer-reviewed results or exact-version equivalence.

Reported sensitivity
84.50% (95% CI: 80.22%, 88.17%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
80.25% (95% CI: 77.33%, 82.95%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

RELIVE: retrospective multi-reader, multi-case assisted-reading study

  • DesignCompleted retrospective observational cohort and controlled multi-reader, multi-case comparison
  • Population480 high-risk lung-cancer screening cases evaluated for pulmonary-nodule detection, localization, and characterization
  • Scopeproduct family
  • Tested versionMedian LCS / eyonis LCS; registry does not identify the FDA submission or software version
  • Samplen=480
  • IndependenceSponsor or vendor study

NCT06751576

Sponsor: Median Technologies. Primary endpoint compares reader patient-level AUROC with and without device assistance.

REALITY: multinational, multicenter retrospective standalone study

  • DesignCompleted multinational, multicenter retrospective observational cohort
  • Population1,147 high-risk lung-cancer screening cases with chest low-dose CT
  • Scopeproduct family
  • Tested versionMedian LCS / eyonis LCS; registry does not identify the FDA submission or software version
  • Samplen=1147
  • IndependenceSponsor or vendor study

NCT06576232

Sponsor: Median Technologies. Primary endpoint is patient-level AUROC, with sensitivity, specificity, PPV, and NPV identified as supporting measures.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

Reimbursement
Medicare National Coverage Determination 210.14 (version effective 2022-02-10) covers annual lung cancer screening with low dose CT under Part B as a preventive service for eligible beneficiaries (age 50-77, asymptomatic, at least 20 pack-years, current smoker or quit within 15 years, with an order and a prior counseling and shared decision-making visit). It requires a board-certified or board-eligible reading radiologist and a facility that uses a standardized lung nodule identification, classification and reporting system. The NCD does not mention AI or nodule-detection software. This is national service-level context, not a determination that this exact product is covered or separately paid. No payment amount or software-specific code was reviewed.
  • Service-level, not product-specific
  • Checked 2026-10-25

No product-specific code

National coverage of the LDCT lung screening service (NCD 210.14); software-specific coverage and payment not established

Medicare (Original Medicare, CMS) · United States · Effective 2022-02-10

The NCD covers the screening service and does not address AI software. It does not prove eligibility, coverage or separate payment for this product, version, patient, site or claim.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Low-dose chest CT DICOM images from high-risk patients eligible for lung cancer screening programs (as per USPSTF criteria), excluding patients with pure ground glass cancer only and hilar/mediastinal cancer; exact specifications are described in a DICOM Conformance Statement.

    Scope: Exact FDA submission. Packet wording: "It is indicated for use with low-dose Chest CT DICOM images. The exact specifications are described in a DICOM Conformance Statement (DCS) document." … "The target population is high-risk patients eligible for participation in lung cancer screening programs (as per USPSTF criteria) with the exception of patients with pure ground glass cancer only and hilar/mediastinal cancer who are excluded from the intended population.". Read from the exact FDA decision document on 2026-11-14.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-11-14 · K251474 FDA 510(k) decision summary

  2. Routing

    Source context, not route validation: The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.

    Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-01 · eyonis® LCS 1.1 model card (K251474)

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-10-27 ·

  4. Returned objects

    Source context, not route validation: Nodule detection, localization, characterization, measurements, and malignancy scores for radiologist review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-08-13 · K251474 FDA 510(k) decision summary

  5. Viewer/worklist/report

    Unresolved route: Nodule detection, localization, characterization, measurements, and malignancy scores for radiologist review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-08-13 · K251474 FDA 510(k) decision summary

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-09-01

Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

Research-study input

Chest low-dose CT DICOM images

product family · checked 2026-09-01

Registry description; exact commercial ingestion and protocol requirements require current technical documentation.

Research-study output

A DICOM result report summarizing detected nodules, localization, characterization, and malignancy score per patient

product family · checked 2026-09-01

Registry description; output routing and viewer behavior require current commercial implementation documentation.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K251474
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-13
Anatomy
Chest/Lung
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-13
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-02-06
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
20Fields reviewed
7Source classes checked
0Awaiting review PubMed leads
2Awaiting review trial leads
0Unreviewed FDA recall leads

Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. ClinicalTrials.gov candidate records were manually matched to the Median LCS / eyonis LCS product family; exact K251474 version equivalence was not established. Automated exact-name discovery found 0 PubMed and 2 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, acr ai central product, clinical trials, payer policy, fda decision summary, pubmed, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-10-27 - Exact FDA submission

    No public price or quote for the exact K251474 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Deployment: Not verified - checked 2026-10-27 - Exact FDA submission

    The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded search 2026-10-26: Median Technologies' eyonis.ai corporate-policies page covers patents, anti-corruption and fair competition only; the legal notice is a website disclaimer; no product security statement located.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-10-27 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

9 sources - 2 history items

Source ledger

  1. K251474 FDA 510(k) decision summary

    U.S. Food and Drug Administration - Accessed 2026-08-13

    Scope: purpose, modality, anatomy, output, limitations

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. eyonis® LCS 1.1 model card (K251474)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. RELIVE: reader study of Median LCS / eyonis LCS

    ClinicalTrials.gov - Accessed 2026-09-01

    Scope: evidenceStudy, population, input, output

  8. REALITY: standalone study of Median LCS / eyonis LCS

    ClinicalTrials.gov - Accessed 2026-09-01

    Scope: evidenceStudy, population, input, output

  9. CMS National Coverage Determination 210.14: Lung Cancer Screening with Low Dose Computed Tomography (LDCT)

    Centers for Medicare & Medicaid Services (Medicare Coverage Database) - Accessed 2026-10-25

    Scope: reimbursement, coverage, payerPolicy

Research history

  1. K251474 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

Alternatives

Related tools to compare

FDA-cleared K213713

AI-Rad Companion (Pulmonary)

Siemens Healthcare GmBh

AI-Rad Companion (Pulmonary) is image processing software that provides quantitative and qualitative analysis from previously acquired Computed Tomography DICOM images to support radiologists and physicians from emergency medicine, specialty care, urgent care, and general practice in the evaluation and assessment of disease of the lungs. It provides the following functionality: Segmentation and measurements of complete lung and lung lobes Identification of areas with lower Hounsfield values in comparison to a predefined threshold for complete lung and lung lobes Providing an interface to external Medical Device syngo.CT Lung CAD Segmentation and measurements of solid lung nodules. Dedication of found lung nodules to corresponding lung lobe. Correlation of segmented lung nodules of current scan with known priors and quantitative assessment of changes of the correlated data. Identification of areas with elevated Hounsfield values, where areas with elevated versus high opacities are distinguished. The software has been validated for data from Siemens Healthineers (filtered back projection and iterative reconstruction),GE Healthcare (filtered back projection reconstruction), and Philips (filtered back projection reconstruction).Only DI COM images of adult patients are considered to be valid input.

Modality
CT/CTA
Anatomy
Chest/Lung
Decision
2022-08-11
FDA-cleared K231157

syngo.CT Lung CAD (Version VD30)

Siemens Healthcare GmbH

Authorized purpose: Assist radiologists in detecting solid and subsolid pulmonary nodules during review of multivendor multi-detector CT examinations of the chest; the device is an adjunctive first- or second-reader tool.

Modality
CT/CTA
Anatomy
Chest/Lung
Decision
2023-07-19

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history